CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Laurus Labs Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Laurus Labs Ltd
Serene Chambers, Road No 7, Banjarahills
Phone: +91 4039804333p:+91 4039804333 HYDERABAD, 500034  India Ticker: LAURUSLABSLAURUSLABS
Business Summary
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, Laurus Synthesis, and Laurus Bio. The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. The Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. The Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board RavindranathKancherla 69 5/18/2024 5/18/2017
Chief Executive Officer, Executive Director SatyanarayanaChava 63 1/1/2022 4/1/2015
Chief Financial Officer, Executive Director Venkata Ravi K.Vantaram 59 1/1/2022 4/1/2015
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Richcore Lifesciences Private Ltd. No 335 12th B Cross 1st Main Bangalore Karnataka India
Laurus Synthesis Inc. 12 Cabot Road Woburn MA United States

Business Names
Business Name
540222
HBV ANDA
Laurus Synthesis Inc.
LAURUSLABS
Richcore Lifesciences Private Ltd.

General Information
Number of Employees: 6,007 (As of 3/31/2024)
Outstanding Shares: 539,252,491 (As of 12/31/2024)
Shareholders: 365,692
Stock Exchange: NSE
Fax Number: +91 4066594320


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025